EUVIMEDEUVIMED entdecken
Crossref

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Ng, Kevin W, Boumelha, Jesse, Enfield, Katey S S, Almagro, Jorge, Cha, Hongui, Pich, Oriol und 48 weitere

Zurich Open Repository and Archive (University of Zurich) · 29.01.2024

DOI: 10.5167/uzh-254318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zurich Open Repository and Archive (University of Zurich), erschienen am 29.01.2024. Verfasst von Ng und 59 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS)$^{1,2}$. Although TLS have been found to correlate with improved patient survival and response to immune checkpoint blockade (ICB), the underlying mechanisms of this association remain elusive$^{1,2}$. Here we investigate lung-resident B cell responses in patients from the TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) and other lung cancer cohorts, and in a recently established immunogenic mouse model for lung adenocarcinoma$^{3}$. We find that both human and mouse lung adenocarcinomas elicit local germinal centre responses and tumour-binding antibodies, and further identify endogenous retrovirus (ERV) envelope glycoproteins as a dominant anti-tumour antibody target. ERV-targeting B cell responses are amplified by ICB in both humans and mice, and by targeted inhibition of KRAS(G12C) in the mouse model. ERV-reactive antibodies exert anti-tumour activity that extends survival in the mouse model, and ERV expression predicts the outcome of ICB in human lung adenocarcinoma. Finally, we find that effective immunotherapy in the mouse model requires CXCL13-dependent TLS formation. Conversely, therapeutic CXCL13 treatment potentiates anti-tumour immunity and synergizes with ICB. Our findings provide a possible mechanistic basis for the association of TLS with immunotherapy response.

Schlagwörter

endogenous retroviruseslung adenocarcinomatertiary lymphoid structuresB cellsimmune checkpoint blockadeCXCL13antitumor immunityimmunotherapy response prediction

Zitieren

APA

Ng, W, K., Boumelha, Jesse, Enfield, S, K. S., Almagro, Jorge, Cha, Hongui, Pich, Oriol, Karasaki, Takahiro, Moore, A, D., Salgado, Roberto, Sivakumar, …, & Maise (2024). Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Zurich Open Repository and Archive (University of Zurich). https://doi.org/10.5167/uzh-254318

Vancouver

Ng, W K, Boumelha, Jesse, Enfield, S KS, et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Zurich Open Repository and Archive (University of Zurich). 2024. doi:10.5167/uzh-254318

BibTeX
@article{Ng2024,
  author = {Ng and W, Kevin and Boumelha and Jesse and Enfield and S, Katey S and Almagro and Jorge and Cha and Hongui and Pich and Oriol and Karasaki and Takahiro and Moore and A, David and Salgado and Roberto and Sivakumar and Monica and Young and George and Molina-Arcas and Miriam and Trécesson, de Carné and Sophie and Anastasiou and Panayiotis and Fendler and Annika and Au and Lewis and Shepherd and C, Scott T and Martínez-Ruiz and Carlos and Puttick and Clare and Black and M, James R and Watkins and K, Thomas B and Kim and Hyemin and Shim and Seohee and Faulkner and Nikhil and Attig and Jan and Veeriah and Selvaraju and Magno and Neil and Ward and Sophia and Frankell and M, Alexander and Bakir, Al and Maise},
  title = {Antibodies against endogenous retroviruses promote lung cancer immunotherapy},
  journal = {Zurich Open Repository and Archive (University of Zurich)},
  year = {2024},
  doi = {10.5167/uzh-254318}
}
Kostenlos starten →